Smith & Nephew plc (LON:SN) Receives Average Rating of “Hold” from Analysts

Smith & Nephew plc (LON:SN) has been given a consensus recommendation of “Hold” by the seven ratings firms that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is GBX 1,185.86.

A number of brokerages recently issued reports on SN. Berenberg Bank reissued a “hold” rating and issued a GBX 13 target price on shares of Smith & Nephew in a research report on Friday, May 1st. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and set a GBX 1,350 target price for the company. in a research report on Thursday, May 7th. Finally, UBS Group reissued a “neutral” rating and issued a GBX 1,300 target price on shares of Smith & Nephew in a research report on Tuesday, May 5th.

Smith & Nephew Stock Performance

SN opened at GBX 1,103 on Thursday. The stock has a market cap of £12.09 billion, a P/E ratio of 39.71, a P/E/G ratio of 0.46 and a beta of 0.67. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The firm has a 50 day simple moving average of GBX 1,211.05 and a 200-day simple moving average of GBX 1,248.86.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.